- Brand names:
- Pharmaceutical Company:
- Condition/Indication: Chronic lymphocytic leukaemia (CLL) or small lymphocytic lymphoma (SLL)
- Meeting Date: November 2025
- Public Summary Document (PSD) November 2025 PBAC Meeting - (PDF 968.3KB)
- Public Summary Document (PSD) November 2025 PBAC Meeting - (Word 294.9KB)
Acalabrutinib – November 2025
Acalabrutinib: Tablet 100 mg; Calquence® - November 2025
Last updated
5 November 2025